Celleron finds international backers for oncology therapeutics

1st February 2017

Oxford spinout Celleron Therapeutics raises funding from South Korean consortium of investors for small molecule treatments.

Celleron Therapeutics, an Oxford University life sciences spinout developing small molecule therapeutics to target cancer, has announced completion of its latest financing round.

Backed by a consortium of South Korean investors, the new funding will be used to advance Celleron’s two drug candidates, CXD101 and CXD201, through clinical trials. The investors include Korea Investment Partners, NHN Investment, IMM Investment, KTB Network, and Theragen Etex.

Press release sign up